Zetia and Nexavar drive Bayer's pharma growth in Japan
This article was originally published in Scrip
Bayer's sales of prescription drugs in Japan grew by just over 9% to ¥171.5 billion ($1.83 billion) at reimbursement prices in calendar 2009, with the increase being driven mainly by high cholesterol product Zetia (ezetimibe) and Nexavar (sorafenib) for cancer.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.